WEBULL
News
RGEN
132.63
-4.86%
-6.77
Repligen Corporation to Announce Fourth Quarter and Full Year Financial Results
Reuters · 2d ago
Repligen Corporation kündigt Veröffentlichung von Finanzergebnissen an
Reuters · 2d ago
Repligen to Report Fourth Quarter and Full Year 2025 Financial Results
Barchart · 2d ago
Weekly Report: what happened at RGEN last week (0202-0206)?
Weekly Report · 3d ago
How Investors May Respond To Repligen (RGEN) Winning Backing For Its AI-Driven Bioprocessing Platform
Simply Wall St · 4d ago
Reassessing Repligen (RGEN) Valuation After Recent Share Price Weakness
Simply Wall St · 6d ago
Weekly Report: what happened at RGEN last week (0126-0130)?
Weekly Report · 02/02 10:11
Q/C Technologies Inc. Files Initial Beneficial Ownership Statement for Director Chelsea Sierra Voss
Reuters · 01/30 22:31
Private Markets: Nvidia, Microsoft consider new investment in OpenAI
TipRanks · 01/30 15:51
Analysts Are Bullish on These Healthcare Stocks: Repligen (RGEN), Definium Therapeutics (DFTX)
TipRanks · 01/29 07:50
Weekly Report: what happened at RGEN last week (0119-0123)?
Weekly Report · 01/26 10:11
Q/C Technologies Appoints AI Expert Chelsea Voss to Board
Reuters · 01/26 07:41
Conestoga Mid Cap Composite Q4 2025 Leaders And Laggards
Seeking Alpha · 01/25 15:09
Old National Bancorp Among 3 Value Stocks Priced Below Estimated Worth
Simply Wall St · 01/22 17:08
Q/C Technologies Appoints Chelsea Voss to Board of Directors
Reuters · 01/20 14:15
Weekly Report: what happened at RGEN last week (0112-0116)?
Weekly Report · 01/19 10:16
Expert Outlook: Repligen Through The Eyes Of 5 Analysts
Benzinga · 01/16 20:00
Repligen Is Maintained at Buy by UBS
Dow Jones · 01/16 18:10
UBS Maintains Buy on Repligen, Raises Price Target to $200
Benzinga · 01/16 18:00
REPLIGEN CORP <RGEN.O>: UBS RAISES TARGET PRICE TO $200 FROM $190
Reuters · 01/16 15:09
More
Webull provides a variety of real-time RGEN stock news. You can receive the latest news about Repligen through multiple platforms. This information may help you make smarter investment decisions.
About RGEN
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.